Vandetanib successfully controls medullary thyroid cancer-related cushing syndrome in an adolescent patient

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages 3055-3059

  Nella, A A ^a   Lodish, M B ^a   Fox, E ^b,c   Balis, F M ^b,c   Quezado, M M ^b   Whitcomb, P O ^b   Derdak, J ^b   Kebebew, E ^b   Widemann, B C ^b   Stratakis, C A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CORTICOTROPIN; HYDROCORTISONE; KETOCONAZOLE; SORAFENIB; SUNITINIB; VANDETANIB; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADOLESCENT; ADRENALECTOMY; BIOCHEMISTRY; BRAZILIAN; CANCER RADIOTHERAPY; CASE REPORT; CONFERENCE PAPER; CUSHING SYNDROME; DEATH; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NEUROFIBROMATOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REMISSION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; COMPLICATION; SECOND CANCER; SECONDARY; SECRETION (PROCESS); THYROID TUMOR;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CUSHING SYNDROME; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NEOPLASMS, SECOND PRIMARY; PIPERIDINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84907226130     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4340     Document Type: Conference Paper

References (25)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998; 83: 2638-2648.
2. Krassas GE, Rivkees SA, Kiess W. Diseases of the thyroid in childhood and adolescence. Basel, New York: Karger; 2007.
3. de Groot JW, Kema IP, Breukelman H, et al. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid. 2006; 16: 1163-1170.
4. Barbosa SL, Rodien P, Leboulleux S, et al. Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid. 2005; 15: 618-623.
5. Baudry C, Paepegaey AC, Groussin L. Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med. 2013; 369: 584-586.
6. More J, Young J, Reznik Y, et al. Ectopic ACTH syndrome in children and adolescents. J Clin Endocrinol Metab. 2011; 96: 1213-1222.
7. Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013; 19: 4239-4248.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
9. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013; 31: 3639-3646.
10. Findling JW, Tyrrell JB. Occult ectopic secretion of corticotropin. Arch Intern Med. 1986; 146: 929-933.
11. Doppman JL, Nieman L, Miller DL, et al. Ectopic adrenocorticotropic hormone syndrome: localization studies in 28 patients. Radiology. 1989; 172: 115-124.
12. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002; 62: 4645-4655.
13. Goldman SJ, Herman CP, Polivy J. Is the effect of a social model on eating attenuated by hunger? Appetite. 1991; 17: 129-140.
14. Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab. 2013; 98: 1333-1342.
15. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-513.
16. Bourcier ME, Vinik AI. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Pancreas. 2013; 42: 348-352.
17. Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012; 97: 4040-4050.
18. Castellano D, Capdevila J, Sastre J, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer. 2013; 49: 3780-3787.
19. Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011; 121: 4712-4721.
20. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004; 23: 6056-6063.
21. Glade Bender J, Yamashiro DJ, Fox E. Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist. 2011; 16: 1614-1625.
22. Bentzien F, Zuzow M, Heald N, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid. 2013; 23: 1569-1577.
23. Martínez-Rodríguez I, Banzo I, Carril JM. Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy. Endocrine. 2013; 44: 264-265.
24. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010; 16: 5260-5268.
25. Lodish MB, Stratakis CA. RET oncogene in MEN2, MEN2B,MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther. 2008; 8: 625-632.